<p>WT-SMCs and CSE-KO-SMCs were treated with estrogen at the indicated concentrations for 72 h, and then cell viability and cell proliferation were measured. Cell viability of WT-SMCs (<b><i>A</i></b>) and CSE-KO-SMCs (<b><i>B</i></b>) were measured by MTT assay and cell proliferation of WT-SMCs (<b><i>C</i></b>) and CSE-KO-SMCs (<b><i>D</i></b>) were analyzed by BrdU incorporation assay. The control cells without estrogen treatment were considered as 100% viable. Data were from five independent experiments. * p<0.05 <i>vs</i>. control group.</p
With controversy surrounding hormone replacement therapy in postmenopausal women, phytoestrogen has ...
<p>A, Schematic presentation of malignant transformation of the breast tumorigenesis cellular model....
Use of estrogen or estrogen/progestin combination was an approved regimen for menopausal hormonal th...
<p>WT-SMCs (<b><i>A</i></b>) and CSE-KO-SMCs (<b><i>B</i></b>) were pretreated with 10 µM U0126 (a M...
<p>In the CC cell lines 786-O, RCC-1, Caki-1, and ACHN, cell growth slowed down in the cells treated...
<p>Approximately 10<sup>4</sup> cells were seeded into microwell plates and allowed to grow over 4 d...
<p><b>the actions of estrogen on the growth of WT-SMCs and CSE-KO-SMCs. </b><b><i>A</i></b><b>,</b> ...
<p>Cells were grown in charcoal-stripped serum, 48 h prior to treatment and were treated with contro...
<p>Cells were exposed to increasing concentrations of tested compounds for 72 h before performing th...
<p>LNCaP C-33 and CAOV-3 cells were plated in duplicates in the regular medium as described in the m...
<p>(A) Doubling time in each group, the mean doubling time is reduced by 12 hours in the E2 group co...
<p>MCF-7 cells with KD of SRC-2 (SRC-2 shRNA) and control shRNA MCF-7 cells (Ctr shRNA) grown in phe...
<p>(A) Western analysis of MCF-7 cells treated with or without 10 nM estradiol or 100 ng/mL PMA for ...
Estrogen increases the ability of the estrogen-dependent MCF-7 human breast cancer cell line to both...
<p>(A) Proliferation of huLM cells expressing different levels of COMT or treated with 2ME (500 nM) ...
With controversy surrounding hormone replacement therapy in postmenopausal women, phytoestrogen has ...
<p>A, Schematic presentation of malignant transformation of the breast tumorigenesis cellular model....
Use of estrogen or estrogen/progestin combination was an approved regimen for menopausal hormonal th...
<p>WT-SMCs (<b><i>A</i></b>) and CSE-KO-SMCs (<b><i>B</i></b>) were pretreated with 10 µM U0126 (a M...
<p>In the CC cell lines 786-O, RCC-1, Caki-1, and ACHN, cell growth slowed down in the cells treated...
<p>Approximately 10<sup>4</sup> cells were seeded into microwell plates and allowed to grow over 4 d...
<p><b>the actions of estrogen on the growth of WT-SMCs and CSE-KO-SMCs. </b><b><i>A</i></b><b>,</b> ...
<p>Cells were grown in charcoal-stripped serum, 48 h prior to treatment and were treated with contro...
<p>Cells were exposed to increasing concentrations of tested compounds for 72 h before performing th...
<p>LNCaP C-33 and CAOV-3 cells were plated in duplicates in the regular medium as described in the m...
<p>(A) Doubling time in each group, the mean doubling time is reduced by 12 hours in the E2 group co...
<p>MCF-7 cells with KD of SRC-2 (SRC-2 shRNA) and control shRNA MCF-7 cells (Ctr shRNA) grown in phe...
<p>(A) Western analysis of MCF-7 cells treated with or without 10 nM estradiol or 100 ng/mL PMA for ...
Estrogen increases the ability of the estrogen-dependent MCF-7 human breast cancer cell line to both...
<p>(A) Proliferation of huLM cells expressing different levels of COMT or treated with 2ME (500 nM) ...
With controversy surrounding hormone replacement therapy in postmenopausal women, phytoestrogen has ...
<p>A, Schematic presentation of malignant transformation of the breast tumorigenesis cellular model....
Use of estrogen or estrogen/progestin combination was an approved regimen for menopausal hormonal th...